<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Product Portfolio on FinanClub</title>
    <link>https://finan.club/tags/product-portfolio/</link>
    <description>Recent content in Product Portfolio on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 13 Dec 2023 09:21:10 +0000</lastBuildDate><atom:link href="https://finan.club/tags/product-portfolio/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ROIV</title>
      <link>https://finan.club/us/roiv/</link>
      <pubDate>Wed, 13 Dec 2023 09:21:10 +0000</pubDate>
      
      <guid>https://finan.club/us/roiv/</guid>
      <description>score:8
Chances: Roivant Sciences Ltd. has shown promising results with its product portfolio, including IMVT-1402 and other medications The appointment of Mayukh Sukhatme, M.D., to its Board of Directors signals a positive addition to the company&amp;rsquo;s leadership Risks: The failure of oral brepocitinib to meet its primary endpoint for Systemic Lupus Erythematosus is a setback for the company Roivant&amp;rsquo;s decision to sell Telavant for $7.</description>
    </item>
    
  </channel>
</rss>
